KALA BIO Inc
kalarx.comKALA BIO Inc (NASDAQ: KALA) is a clinical-stage biotechnology company that, as of its FY2025 10-K filed April 15, 2026, has ceased its primary drug development operations and is pursuing a pivot toward AI-based biotechnology research tools. The company's lead therapeutic program, KPI-012, a mesenchymal stem cell secretome platform targeting persistent corneal epithelial defects, was abandoned in September 2025 after the CHASE clinical trial failed to meet its primary endpoint. Following that failure, Oxford Finance foreclosed on substantially all company assets, and KALA terminated the majority of its workforce. The company has since licensed the Researgency platform, an agentic AI and private enterprise large language model system aimed at biotechnology research workflows, though it had not recognized revenue from this initiative as of the filing date. David Lazar was appointed CEO and Chair in November 2025 following the terminations of prior CEO Todd Bazemore and CFO Mary Reumuth. KALA has traded on the Nasdaq Capital Market under the symbol KALA since January 11, 2023, and faces potential delisting due to non-compliance with Nasdaq bid price requirements as of the filing date.
Products & Services
KPI-012: mesenchymal stem cell secretome topical ophthalmic therapy for persistent corneal epithelial defects, development ceased September 2025. Researgency Platform: licensed agentic AI and private enterprise large language model system targeting biotechnology research workflows, including clinical dataset analysis, literature synthesis, and report generation. No revenue recognized from Researgency as of the filing date.
Revenue Model
No product revenue has been recognized from KALA's AI platform initiative (Researgency) as of the FY2025 filing. The company historically operated as a pre-commercial clinical-stage biotech with no disclosed commercial product revenue from KPI-012, which was abandoned in September 2025. Capital was raised through equity issuances including at-the-market offerings, common stock offerings, and convertible preferred stock series (Series G, H, and I) as reflected in FY2024 and FY2025 financial statements.
Customers & Markets
Potential customers for the Researgency platform are biotechnology and pharmaceutical organizations seeking private AI deployments for research workflows. No commercial customers or revenue reported as of FY2025 filing. Prior therapeutic end market was ophthalmology, specifically patients with persistent corneal epithelial defects.
Geographic Exposure
Headquartered in the United States. Former laboratory and R&D space was located in Menlo Park, California, under a lease terminated during Q4 2025. No international operations disclosed in the filing.
Financial Snapshot
Loading...
